Crenezumab Fails to Meet Primary Endpoints in Preclinical Autosomal-Dominant Alzheimer’s: Insights from the API ADAD Colombia Trial
A Phase 2 trial of crenezumab in cognitively unimpaired PSEN1 mutation carriers found no significant clinical benefit over 5-8 years, suggesting that robust amyloid plaque removal may be essential for disease modification in early-stage Alzheimer's.